title: Bioactive components of Chinese herbal medicine enhance endogenous neurogenesis in animal models of ischemic stroke: A systematic analysis.
abstract: BACKGROUND
  Chinese herbal medicine (CHM) has been used to treat stroke for thousands of years. The objective of the study is to assess the current evidence for bioactive components of CHM as neurogenesis agent in animal models of ischemic stroke.
  
  
  METHODS
  We searched PubMed, China National Knowledge Infrastructure, WanFang Database, and VIP Database for Chinese Technical Periodicals published from the inception up to November 2015. The primary measured outcome was one of neurogenesis biomarker, including Bromodeoxyuridine (BrdU), Nestin, doublecortin (DCX), polysialylated form of the neural cell adhesion molecule (PSA-NCAM), neuronal nuclear antigen (NeuN), and glial fibrillary acidic protein (GFAP).
  
  
  RESULTS
  Thirty eligible studies were identified. The score of quality assessment ranged from 2 of 10 to 7 of 10. Compared with controls, 10 studies conducting neurobehavioral evaluation showed significant effects on bioactive components of CHM for improving neurological deficits score after ischemic insults (P < 0.01 or P < 0.05); 6 studies in Morris water-maze test showed bioactive components of CHM significantly decreased escape latency and increased residence time (P < 0.05); 5 studies demonstrated that bioactive components of CHM significantly reduced infarct volume after ischemic stroke (P < 0.05); 25 of 26 studies showed that bioactive components of CHM significantly increased the expression of BrdU and/or Nestin markers in rats/mice brain after ischemic injury (P < 0.05, or P < 0.01); 4 of 5 studies for promoting the expression of PSA-NCAM or DCX biomarker (P < 0.05); 5 studies for improving the expression of NeuN biomarker (P < 0.05); 6 of 7 studies for promoting the expression of GFAP biomarker in brain after ischemic stroke (P < 0.05).
  
  
  CONCLUSIONS
  The findings suggest that bioactive components of CHM may improve neurological function, reduce infarct volume, and promote endogenous neurogenesis, including proliferation, migration, and differentiation of neural stem cells after ischemic stroke. However, evidences are supported but limited because only a few studies were available for each descriptive analysis. Further rigor study is still needed.
authors.affiliation: Department of Neurology, the Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou School of Chinese Medicine, Hong Kong Baptist University, Hong Kong SAR, China Department of Neurology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China.
authors.forename: Ji-Huang
authors.initials: JH
authors.lastname: Li
authors.forename: Zi-Xian
authors.initials: ZX
authors.lastname: Chen
authors.forename: Xiao-Guang
authors.initials: XG
authors.lastname: Zhang
authors.forename: Yan
authors.initials: Y
authors.lastname: Li
authors.forename: Wen-Ting
authors.initials: WT
authors.lastname: Yang
authors.forename: Xia-Wei
authors.initials: XW
authors.lastname: Zheng
authors.forename: Shuang
authors.initials: S
authors.lastname: Chen
authors.forename: Lin
authors.initials: L
authors.lastname: Lu
authors.forename: Yong
authors.initials: Y
authors.lastname: Gu
authors.forename: Guo-Qing
authors.initials: GQ
authors.lastname: Zheng
mesh_terms: D000818:Animals; D015415:Biomarkers; D004195:Disease Models, Animal; D000089662:Doublecortin Protein; D004365:Drugs, Chinese Herbal / Q000737:chemistry / Q000494:pharmacology*; D055495:Neurogenesis / Q000187:drug effects*; D020521:Stroke / Q000188:drug therapy* / Q000503:physiopathology
chemical_list: D015415:Biomarkers; C000714847:Dcx protein, mouse; C000714848:Dcx protein, rat; D000089662:Doublecortin Protein; D004365:Drugs, Chinese Herbal